Phase 1 study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC Meeting Abstract
| Authors: | Jänne, P.; Yu, H.; Shipitofsky, N.; Vigliotti, M.; Goldberg, T.; Li, J.; Mcgill, J.; Zhang, H.; Yu, C. |
| Abstract Title: | Phase 1 study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC |
| Meeting Title: | IASLC 19th World Conference on Lung Cancer |
| Keywords: | drug resistance; egfr; axl |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 13 |
| Issue: | 10 Suppl. |
| Meeting Dates: | 2018 Sep 23-26 |
| Meeting Location: | Toronto, Canada |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2018-10-01 |
| Start Page: | S801 |
| Language: | English |
| ACCESSION: | WOS:000454014503066 |
| DOI: | 10.1016/j.jtho.2018.08.1403 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P2.13-08 -- Source: Wos |
